Amgen Sees Strong Q4 Growth Even Without Horizon Contribution

Gains Driven By Volume For Many Products

The company increased its full-year guidance in anticipation of Horizon’s Q4 contribution and sales for the quarter jumped 20%, but even excluding those drugs product sales were up 5%.

Amgen's full-year 2024 revenue guidance is $32.4bn-$33.8bn • Source: Shutterstock

Amgen, Inc.’s revenue surged during the fourth quarter of 2023, powered largely by the rare disease drug portfolio from its $27.8bn Horizon Therapeutics plc acquisition that closed during the quarter, but the company also saw significant growth for several products outside of those assets, including the osteoporosis drugs Prolia (denosumab) and Evenity (romosozumab) and LDL-lowering therapy Repatha (evolocumab).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Quick Listen: Scrip’s Five Must-Know Things

21 Apr 2025

• By Ian Haydock

In this week's episode: Trump’s drug pricing executive order; J&J says taxes, not tariffs, influence US manufacturing; Pfizer discontinuation sparks M&A speculation; US tariffs and manufacturing concentration; and tariffs’ pressures on pharma’s complex supply chain.

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

18 Apr 2025

• By Jung Won Shin, Lisa Takagi, Joseph Haas, Anju Ghangurde, and Vibha Ravi

Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.

Cancer Retains Top Spots In Alliance Deal Volume, Value

18 Apr 2025

• By Joseph Haas

Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.